Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 18/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2724678 | 0.91 | PIK3CG (0.47) | PIK3CDPIK3CG | |
| SCHEMBL2722160 | 0.86 | PIK3CD (0.44) | PIK3CDPIK3CGMAPT | |
| SCHEMBL4297407 | 0.86 | PIK3CD (0.50) | PIK3CDPIK3CGMAPT | |
| SCHEMBL15199261 | 0.84 | PIK3CG (0.47) | PIK3CDPIK3CGMAPT | |
| SCHEMBL10044536 | 0.80 | PIK3CD (0.67) | PIK3CDPIK3CG | |
| SCHEMBL4291889 | 0.80 | PIK3CG (0.62) | PIK3CDPIK3CG | |
| SCHEMBL2721509 | 0.79 | PIK3CG (0.55) | PIK3CDPIK3CGMAPT | |
| SCHEMBL4291645 | 0.79 | PIK3CG (0.49) | PIK3CDPIK3CGMAPT | |
| SCHEMBL15199272 | 0.78 | PIK3CD (0.47) | PIK3CDPIK3CG | |
| SCHEMBL4289834 | 0.78 | MAPT (0.47) | PIK3CDPIK3CGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630129-B1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | claimed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | claimed |
| EP-2630129-A1 | QUINOXALINE DERIVATES | Merck Patent GmbH (DE) | 2013-08-28 | — | — | EP | claimed |
| WO-2012052102-A1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2012-04-26 | — | — | WO | claimed |
| EP-2630129-B1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-2630129-B1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| EP-2630129-A1 | QUINOXALINE DERIVATES | Merck Patent GmbH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| WO-2012052102-A1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052102-A1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | PIK3R5, NQO2, PIK3R1 | PIK3CD 14/4885PIK3CG 8/4885MAPT 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.